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REPORT
Nemaline Myopathy with Minicores Caused by Mutation
of the CFL2 Gene Encoding the Skeletal Muscle Actin–Binding
Protein, Cofilin-2
Pankaj B. Agrawal, Rebecca S. Greenleaf, Kinga K. Tomczak, Vilma-Lotta Lehtokari,
Carina Wallgren-Pettersson, William Wallefeld, Nigel G. Laing, Basil T. Darras,
Sutherland K. Maciver, Philip R. Dormitzer, and Alan H. Beggs
Nemaline myopathy (NM) is a congenital myopathy characterized by muscle weakness and nemaline bodies in affected
myofibers. Five NM genes, all encoding components of the sarcomeric thin filament, are known. We report identification
of a sixth gene, CFL2, encoding the actin-binding protein muscle cofilin-2, which is mutated in two siblings with
congenital myopathy. The proband’s muscle contained characteristic nemaline bodies, as well as occasional fibers with
minicores, concentric laminated bodies, and areas of F-actin accumulation. Her affected sister’s muscle was reported to
exhibit nonspecific myopathic changes. Cofilin-2 levels were significantly lower in the proband’s muscle, and the mutant
protein was less soluble when expressed in Escherichia coli, suggesting that deficiency of cofilin-2 may result in reduced
depolymerization of actin filaments, causing their accumulation in nemaline bodies, minicores, and, possibly, concentric
laminated bodies.
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Nemaline myopathy (NM forms 1–6 [MIM 609284,
256030, 161800, 609285, 605355, and 609273]), the most
common form of congenital myopathy, is a diagnosis
applied to a clinically and genetically heterogeneous col-
lection of patients characterized by weakness and the
presence of rodlike structures called “nemaline bodies”
in affected muscles.1–4 Ultrastructurally, nemaline bodies
appear to originate from sarcomeric Z-disks involving
the adjacent thin filaments where the primary abnor-
malities lie. Mutations of the genes encoding the thin-
filament proteins nebulin (NEB) and skeletal muscle
a-actin (ACTA1) account for a majority of NM cases,5–7
whereas mutations of the genes encoding troponin T1
(TNNT1),8 b-tropomyosin (TPM2),9 and a-tropomyosin
(TPM3)10,11 are quite rare, each having been reported in
only one or several independent families with NM. Ad-
ditionally, NM in two families with autosomal dominant
inheritance is in linkage with an unknown gene on chro-
mosome 15q.12 Despite extensive searches, the genetic ba-
sis for NM, in a significant number of cases, remains
unknown.
Cofilin-2, encoded by CFL2 on chromosome 14q12
(MIM 601443), is a member of the AC group of proteins
that also includes cofilin-1 (encoded by CFL1) and destrin
(encoded by DSTN), all of which regulate actin-filament
dynamics.13,14 CFL2 encodes a skeletal muscle–specific iso-
form15 localized to the thin filaments where it exerts its
effect on actin, in part through interactions with tropom-
yosins.16 Despite an earlier study that found no CFL2 mu-
tations in 50 patients with NM,17 we considered that this
remained an excellent candidate gene because of its crit-
ical role in regulation of sarcomeric actin filaments.
Using genomic PCR and DNA sequencing,17 we screened
the CFL2 gene in 113 unrelated patients with NM and 58
patients with clinicopathological diagnoses of other con-
genital myopathies (i.e., 10 myotubular myopathy, 6 cen-
tronuclear myopathy, 9 multiminicore disease, 6 congen-
ital muscular dystrophy, 2 spheroid body myopathy, 2
Walker-Warburg syndrome, and 23 with nonspecific con-
genital myopathies). All study subjects were enrolled, after
appropriate informed consent, under the supervision of
the Children’s Hospital Boston institutional review board.
None of the patients had known mutations in previously
identified genes. A homozygous missense mutation of
CFL2 was identified in two affected siblings in a large fam-
ily of Middle Eastern origin (fig. 1A). Both patients had
similar clinical presentations, with hypotonia noted at
birth, delayed early motor milestones, frequent falls, and
the inability to run. The elder sister, now age 16 years, can
walk short distances but uses a wheelchair outside the
house. She was given a diagnosis of nonspecific congenital
myopathy at age 4 years, when her muscle biopsy sample
showed marked fiber-size variability, type I fiber predom-
inance, and a few fibers on oxidative stains that exhibited
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Figure 1. Pathologic and genetic findings in a family with CFL2 mutation A35T. A, Partial pedigree of the family illustrates several
consanguineous loops. The proband is indicated by an arrow. The two affected sisters (filled circles) are homozygous for A35T, whereas
an unaffected sister, both parents, and several other members of the extended family (half-filled circles) are heterozygous for the change
and for a shared haplotype spanning ∼4.6-Mb pairs around the CFL2 gene. Green symbols indicate tested individuals with WT sequence.
Light microscopic findings in proband’s muscle include presence of nemaline bodies (B, arrow) on Gomori trichrome staining and
occasional minicores (C, arrow) on nicotinamide adenine nucleotide dehydrogenase-tetrazolium reductase staining. Electron microscopy
confirmed identity of nemaline bodies (D, arrow), unstructured minicores (E, arrow), and concentric laminated bodies (F, arrow). G, DNA
sequence analysis of genomic PCR products illustrating three genotypes for CFL2 c.103GrA seen in the family. H, Schematic representation
of cofilin-2. Residue 35 is located next to NLS (30–34 aa); ABDp actin-binding domain. I, Altered alanine residue (red) is evolutionarily
conserved among AC proteins (i.e., cofilin-2, cofilin-1, and destrin) across all sequenced vertebrates.
focal loss of integrity consistent with minicores. The youn-
ger sibling (proband), now age 9 years, is ambulant and
was given a diagnosis of NM at age 2 years, after a muscle
biopsy sample showed nemaline bodies as well as occa-
sional minicores and concentric laminated bodies (fig. 1B–
1F). The course of the disease in both siblings has been
like that of the “typical” form of NM, but the distribution
of weakness is distinct, since no significant facial weakness
or foot drop was evident.
The proband and her affected sibling are homozygous
for CFL2 c.103GrA, predicted to result in an alanine-to-
threonine substitution at residue 35 (A35T) (fig. 1G and
1H). A35 is located next to a nuclear localization signal
(NLS) (fig. 1H) in a region that is highly conserved across
vertebrates (fig. 1I). An unaffected sibling, both unaffected
parents, and a number of other extended family members
were heterozygous for this change. Extensive intermar-
riage, with multiple consanguineous loops, strongly sug-
gested identity by descent for the two mutant alleles, a
supposition that was supported by linkage studies that
used flanking markers. Linkage analysis, assuming auto-
somal recessive inheritance of a disease gene with a fre-
quency of 0.005, gave a LOD score of 1.9 with a recom-
bination fraction of 0. The mutation was ruled out in 282
unaffected control individuals, including 91 originating
from the same geographic region and ethnic group as the
family.
Indirect immunofluorescence analysis of the proband’s
muscle with the use of anti-a-actinin-2 antisera showed
that, as expected, the nemaline bodies contained this pro-
tein (fig. 2A–2F). Interestingly, despite the fact that mu-
tation of the a-actin gene, ACTA1, had been previously
ruled out, this biopsy sample also exhibited features of an
actinopathy,5 since phalloidin staining of the same sec-
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Figure 2. Fluorescence microscopic analysis revealinga-actinin-
2–positive nemaline bodies and actin-filament accumulations. Un-
affected control muscle (A–C) and the proband’s muscle (D–I) were
immunostained with anti-a-actinin-218 (A and D), anti-skeletal
actin (clone 5C5 anti-sarcomeric actin [Sigma A2172]) (G), and
phalloidin Alexa Fluor 546 (Invitrogen) (B, E, and H). Merged
images, including blue DAPI-stained nuclei, are shown in panels
C, F, and I. Several a-actinin–positive nemaline bodies are indi-
cated by arrows in panels D and F, whereas nonoverlapping F-actin
accumulations are indicated by arrowheads in panels E–I. Scale
bars equal 20 mm (C, F, and I).
tions revealed that 4% of myofibers contained distinct
actin-filament accumulations (fig. 2E and 2H) that stained
equally well with phalloidin (specific for F-actin) and anti-
sarcomeric actin, which binds both G- and F-actin (fig.
2G–2I).
To establish whether the A35T mutation was associated
with altered cofilin-2 expression and/or localization, we
performed immunofluorescence analysis of cofilins in
the proband’s muscle biopsy sample and in several age-
matched unaffected human skeletal muscle specimens.
On longitudinal sections of control muscles, anti-cofilin
antibodies stained in a sarcomeric pattern that colocalized
with actin at I-bands, as expected for cofilin-2 (data not
shown). Remarkably, sarcomeric cofilin-2 staining was sig-
nificantly less intense in the patient muscle fibers relative
to those of age-matched unaffected controls (fig. 3A–3F)
and several other patients with NM (data not shown).
Cross-reactivity of anti-cofilin-2 antibody with cofilin-1
led to interstitial tissue staining of both the patient and
control muscle, providing an internal control for staining.
To determine if the immunofluorescence data reflected
presence of smaller quantities of cofilin-2 in the patient’s
muscle, we performed two-dimensional SDS-PAGE and
immunoblotting, to separate phosphorylated and un-
phosphorylated forms of cofilins 1 and 2. Relative to age-
matched control muscles, unphosphorylated cofilin-2 in
the proband’s muscle was significantly lower, and phos-
phorylated forms were not detectable (fig. 3G).
Quantitative RT-PCR of CFL2 mRNA was used to deter-
mine if the apparent reduction in cofilin-2 protein seen
in the patient’s muscle was caused by lower transcription
and/or mRNA stability. Instead, we found that the pro-
band’s muscle contained between 4- and 20-fold more
CFL2 mRNA, compared with three unaffected, age-
matched control muscle specimens. Thus, the relative ab-
sence of cofilin-2 in the patient’s myopathic muscles was
likely a consequence of reduced protein stability and/or
some other posttranscriptional mechanism(s).
To better understand the effects of the A35T mutation
on cofilin-2 structure, we modeled this change into a nu-
clear magnetic resonance structure of chicken cofilin-2
(Protein Data Bank identification number 1TVJ). Chicken
cofilin-2 differs from human cofilin-2 by three amino acid
differences that are unlikely to affect the conformation of
the region around residue 35. Two of these differences,
P26Q and K44R, are located on highly solvent exposed
loops that are spatially remote from residue 35. The third,
A70S, is adjacent to F71 on a-helix 3. The F71 aromatic
ring contributes to the hydrophobic core that includes the
A35 methyl group. However, as the alanine or serine 70
side chains are solvent exposed, the difference is unlikely
to distort the helix. A35 is in the middle of a b-sheet, with
its backbone amide and carbonyl hydrogen bonded to the
backbone carbonyl and amide of I55. A35 and I55 are both
highly conserved among vertebrate members of the AC
family.19 Modeling T35 with use of the common rotamer
that minimizes clashes with neighboring side chains re-
vealed a distance between Cg2 of T35 and Cb of I55 of
only 2.1 A˚, closer than that allowed by Van der Waals
interactions (fig. 3H). Consequently, some distortion of
the central b-sheet would be required to accommodate the
T35 side chain, although this distortion would not nec-
essarily break any hydrogen bonds.
Since the modeling of T35 suggested a conformational
change in the b-sheet, we next expressed the wild-type
(WT) and A35T cofilin-2 proteins in eukaryotic and pro-
karyotic systems. We constructed matched expression vec-
tors containing the WT and c.103GrA mutant sequences
in the full-length human CFL2 cDNA cloned into mam-
malian expression vectors pcDNA-DEST-47 (C-terminal
green fluorescent protein [GFP] fusion) and pcDNA-3.2-
DEST (C-terminal V5 tag) and bacterial expression vectors
pDEST-42 (C-terminal V5-6x His fusions) and pDEST-14
(no fusion) (all Invitrogen Life Technologies). No differ-
ences were observed between C2C12 myoblasts trans-
fected with either GFP or V5-tagged WT and A35T cofilin-
2 clones; both proteins were uniformly distributed
throughout the cytoplasm.20 After several days of high-
level expression, both transduced cofilins organized into
cytoplasmic and nuclear rod structures, and continued
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Figure 3. Effects of the A35T mutation on cofilin-2 structure and expression in vivo. A–F, Indirect immunofluorescence analysis of
cofilins (green stain [A, C, D, and F]) and skeletal actin (clone 5C5 anti-sarcomeric actin [Sigma A2172]) (red stain [B, C, E, and F])
merged with DAPI for visualization of nuclei (blue stain [C and F]) in muscle from control (A–C) and proband (D–F). Scale bar equals
50 mm. The anti-cofilin-2 polyclonal rabbit antibody (US Biologicals C7506-50) recognizes both sarcomeric cofilin-2 and nonmuscle
cofilin-1 (seen in actin-negative connective tissue). Cofilin-2 staining in myofibers is markedly less intense in the proband compared
with that in the control, but cofilin-1 staining is preserved in connective tissue and capillaries. G, Two-dimensional gel and Western
blot analysis of cofilins in control (c) and proband muscle (pt) performed as described elsewhere.17 On each gel, 200 mg total muscle
lysate proteins were loaded. Equal protein concentrations of lysates were confirmed by immunoblotting parallel SDS-PAGE gels that
were stained for glyceraldehyde-3-phosphate dehydrogenase. Isoelectric focusing was accomplished on a pH gradient of 3–10, and
immunodetection used an antibody that detects both phosphorylated and unphosphorylated cofilin-1 and cofilin-2 (catalog number
C8736 [Sigma]). Identities of the various spots were confirmed using additional isoform-specific and phosphorylation-specific antibodies
(not shown). Although unphosphorylated cofilin-1 spots are similar in intensity, both spots for cofilin-2 are significantly smaller in the
patient’s muscle. H, A35T mutation, modeled using O and Molscript, illustrating side-chain clash of T35 with I55. Residue 35 is in the
middle of a b-sheet, with its backbone amide and carbonyl making hydrogen bonds to the backbone carbonyl and amide of I55. In
this model, the T35 side-chain hydroxyl forms part of a narrow canyon wall on the molecular surface, which is probably filled with
solvent, allowing hydrogen bonds between water molecules and the T35 hydroxyl.
high-level expression eventually resulted in loss of cofilin-
expressing cells, presumably because of cell-cycle arrest21
(data not shown).
In contrast, A35T and WT cofilin-2 proteins behaved
quite differently when expressed in bacteria. Both proteins
were expressed as His fusions in Escherichia coli and were
purified using His-affinity chromatography on Ni-NTA
agarose columns (Qiagen). Although similar amounts of
WT and A35T protein were found in the initial whole-cell
lysates, the purified fractions repeatedly demonstrated se-
lective loss of the mutant but not the WT proteins (fig.
4A). Cell lysis and purification in the presence of 6 M urea
resulted in similar yields for both versions of the protein,
suggesting that the loss of A35T mutant cofilin-2 was a
result of decreased stability and/or solubility. To rule out
the possibility that the His/V5 tag itself might affect the
solubility, each protein was expressed without any fusion
tags, and the expressed proteins were purified using Vi-
vapure D anion exchange columns (Vivascience). As be-
fore, similar amounts of both proteins were present in
total cell lysates, but purification resulted in complete loss
of the A35T samples (fig. 4B). The first step of the puri-
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Figure 4. Differential solubility of WT and mutant cofilin-2. A,
SDS-PAGE analysis of cofilin-2 with His/V5 tag expressed in E. coli.
The amount of mutant cofilin-2 (arrowhead) in the soluble and
purified fractions (lanes 1 and 3) is markedly lower than in the
WT (lanes 2 and 4), even though equal amounts of both proteins
were present in whole bacterial cell lysates (not shown). In con-
trast, when 6 M urea is added to the lysis buffer, the amounts of
mutant and WT cofilin-2 are similar in both supernatant and pu-
rified fractions (lanes 5–8). B, SDS-PAGE analysis of the native
cofilin-2 proteins expressed in E. coli without epitope tags. Iden-
tity of cofilin-2 was confirmed by western blotting (not shown).
As above, A35T protein failed to purify by standard methods (lanes
1 and 2). Analysis of whole bacterial-cell lysates showed roughly
equal amounts of A35T and WT protein produced (lanes 3 and 4),
but only WT protein was soluble and present in centrifuged su-
pernatants (lanes 5 and 6). Treatment of the insoluble fractions
with 6 M urea resulted in recovery and purification of the A35T
proteins (lanes 7–10).
fication procedure involved centrifugation to remove in-
soluble material from the initial lysates. When these pel-
lets were treated with 6 M urea, we found that the mutant
A35T protein was preferentially recovered, demonstrating
that the mutation likely causes protein misfolding in this
prokaryotic expression system, leading to precipitation
and loss in the insoluble fractions during purification (fig.
4B).
We hypothesize that misfolding or destabilization of the
protein’s tertiary structure leads to premature degradation
of the protein in vivo, so the mechanism of disease is likely
related to reduction in the amount of cofilin-2. Deter-
mining whether or not reduced cofilin-2 is a useful di-
agnostic marker for CFL2 mutations will require identifi-
cation of additional patients with different mutations, but
it is noteworthy that only some pathogenic Caenorhabditis
elegans UNC-60B (cofilin-2) mutations resulted in reduced
levels of this protein.22
The pathology of affected muscles in our proband was
remarkable for simultaneous presence of nemaline bodies,
minicores, and concentric laminated bodies. Whereas
nemaline bodies are associated with abnormalities of thin-
filament proteins, concentric laminated bodies are pos-
tulated to be organized aggregates of excessive actin fila-
ments,23 and both these and the minicores24 may in fact
represent the ultrastructural correlates for the F-actin ac-
cumulations seen by immunofluorescence and phalloidin
staining (fig. 2). Similar patterns of staining for both total
sarcomeric actin and phalloidin-stained F-actin support a
hypothesis that the lower amounts of cofilin-2 result in
reduced depolymerization of actin filaments, causing their
accumulation in concentric laminated bodies, nemaline
bodies, and minicore regions.
In summary, we have identified mutation of a sixth
thin-filament–related gene, CFL2, associated with an un-
usual form of NM. To our knowledge, this represents the
first reported instance of mutation in any AC-gene-family
member in humans. We estimate the frequency of CFL2
mutations in patients with NM at well below 0.6%. The
rarity of CFL2 mutations is not surprising in the context
that only a single instance of TNNT1 mutation has been
found to date,8 whereas only two TPM2 mutations are
known in patients with NM.9 The neuropathologist’s di-
agnosis of the proband’s condition was unequivocally
NM; however, occasional minicores and areas of filamen-
tous-actin accumulation were also present in few fibers.
Since both nemaline bodies and minicores may occasion-
ally be nonspecific and the older sister presented with
an undefined congenital myopathy, mutations of CFL2
should be considered possible in patients with any of these
findings.
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